Prostate cancer stands as a prevalent threat to men's health, ranking second in cancer-related deaths in the United States. Each year, approximately 250,000 men in the U.S. receive a prostate cancer ...

In this cohort study, a novel prognostic model was developed to estimate prostate cancer-specific mortality (PCSM) while ...

Individual patient data (IPD) analysis of early PSA nadir in ARASENS, LATITUDE, and TITAN: Training and validation of a novel model. Assessing genomic instability (GI) by shallow whole-genome ...

Benefits include better discrimination between risk levels. (HealthDay News) — Patient-centered pathology reports (PCPR) help patients to understand prostate cancer results better than current ...

If you’ve recently been diagnosed with prostate cancer, or if you’ve had a prostate biopsy to test for prostate cancer, you might have seen the term “Gleason score” or “Gleason grade” on the pathology ...

Growing evidence indicates that more patients with favorable Grade Group 2 prostate cancer can be successfully managed with active surveillance and achieve acceptable oncologic outcomes, even if later ...

Human tissue is intricate, complex and, of course, three dimensional. But the thin slices of tissue that pathologists most often use to diagnose disease are two dimensional, offering only a limited ...

SAN FRANCISCO--(BUSINESS WIRE)--Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, announced today that the U.S. Food and Drug ...

Urological malignancies, including prostate, bladder, renal, and testicular cancers, represent a major global health burden and display remarkable ...

DEAR DR. ROACH: I am a 66-year-old white male who is active and relatively healthy. I have recently been diagnosed with prostate cancer. One blood test showed a PSA level of 13 ng/mL, and a second was ...